Skip to main
CLGN

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies is a regenerative and aesthetic medicine company with a strong focus on 3D bioprinting of tissues and organs. Despite challenges in the broader capital environment, the company remains dedicated to advancing its rhCollagen and BioInk programs, and currently has a promising partnership and revenue model with a diversified source of income streams. While the recently announced registered direct offering may result in near-term dilution risk, the company's long-term potential and innovative technology make it a compelling investment opportunity.

Bears say

CollPlant Biotechnologies is facing several fundamental risks, including clinical and regulatory challenges, partnership uncertainties, financial concerns, commercial obstacles, legal and intellectual property uncertainties, and the potential for loss of market share. Additionally, the company's revenues are currently low, and it has announced a reduction initiative which may indicate cost-cutting measures in response to financial strain. As of September 30, 2025, the company had a minimal amount of cash and cash equivalents, indicating potential liquidity concerns.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.